Skip to main content
. 2015 May 4;3(3):e00136. doi: 10.1002/prp2.136

Figure 5.

Figure 5

Effect of Saroglitazar on lipids in various animal models (A) effect on % change in serum triglyceride versus control and (B) effect on atherogenic dyslipidemia (TG/HDL-C) ratio in high fat-high cholesterol (HF-HC) diet fed Syrian Golden hamsters. Hamsters were kept on HF-HC diet and compound treatment was done for 14 days at 0.03, 0.1, 0.3, 1, 3, and 10 mg/kg. (C) Effect on serum triglyceride clearance in Swiss albino mice. Mice were treated with the compound for 6 days at 0.01, 0.03, 0.1, 0.3, 1, 3, and 10 mg/kg, and on day 7 overnight fasted animals were injected with 3.3% Intralipid as described in Methods. The values are calculated as percent change versus control and expressed as mean ± SEM (n = 7). #Indicates significantly different from normal diet control and *Indicates significantly different from HF-HC diet control P < 0.05 (ANOVA). In Figure (C) at 30 min serum triglyceride levels were significant (P < 0.05) at all doses of Saroglitazar, at 60 min time point 0.1–10 mg/kg dose levels and at 120 min time point 1–10 mg/kg dose levels showed significantly (P < 0.05) lowered triglyceride levels as compared to control group animals.